Researchers at Lawrence Livermore National Laboratory in Livermore, Calif., recently received $3 million from the National Institutes of Health to acquire a new biomedical accelerator mass spectrometry instrument. The instrument will provide analysis for medical and other biological research.

Li Sun, PhD, associate professor of mechanical engineering at University of Houston’s Cullen College of Engineering, has received a three-year, $300,000 grant from the National Science Foundation to develop a new class of contrast agents to provide color to MRI images.

Novelos Therapeutics has completed its acquisition of Cellectar and $5.1 million financing to develop three novel cancer-targeted compounds.

Seven new research projects on regenerative medicine and nanomedicine received $16 million in funding. The studies were co-funded by the Canadian Institutes of Health Research and the Canadian Space Agency.

One of the most promising radiopharmaceuticals is the proliferation marker 3'-deoxy-3'-[18F] fluorothymidine (18F-FLT). Here we discuss examples that could begin to move into clinics over the next two years or more to better predict early response to treatment in ovarian cancer and gliomas, evaluate bone marrow transplant and visualize stem cells in the brain.